U.S. Treasury proposes curbs on Chinese biotech and AI deals

The U.S. Treasury is proposing restrictions on deals involving Chinese biotechnology and artificial intelligence businesses, according to the report. The measures remain at the proposal stage.^[1]

The reported prohibitions could cut major pharmaceutical companies off from Chinese biotechs, which supply many promising cancer treatments.^[1]

Drug licensing lets a developer receive payments in exchange for giving a partner rights to develop or sell a treatment. If restrictions cover those deals, Chinese biotechs could lose licensing income and commercial partners, while major drugmakers may need to find other sources of medicines for future development. The impact depends on which transactions the final restrictions cover.^[1]

Impact

• Chinese biotech and drug developmentRisk

  Developers seeking licensing agreements with major drugmakers could face fewer partnership opportunities. If their deals are restricted, licensing payments that help fund further development could shrink.^[1]

• Major pharmaceutical companiesRisk

  Drugmakers that rely on Chinese biotechs to replenish their medicines under development may need alternative partners. The risk is reduced access to promising cancer treatments.^[1]

• China-linked AI transactionsRisk

  Businesses planning relevant AI deals face uncertainty over whether transactions could proceed. The proposal adds policy risk, although the supplied report does not identify the AI activities or deal types covered.^[1]